Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company established in May 2018 and headquartered in Foster City, California, USA. The company is dedicated to developing and commercializing novel therapies for rare and orphan diseases, particularly focusing on cholestatic liver diseases. Its mission centers on addressing critical unmet medical needs for patients with these conditions.

Mirum's commercial portfolio includes LIVMARLI® (maralixibat), an orally administered IBAT inhibitor approved for cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). The company also markets CHOLBAM® (cholic acid) for bile-acid synthesis disorders and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline features volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV), and MRM-3379 for Fragile X syndrome (FXS).

Mirum Pharmaceuticals is a publicly traded company on NASDAQ under the ticker symbol MIRM, with a market capitalization around $5.7 billion. Chris Peetz serves as the Chief Executive Officer and co-founder. In December 2025, the company announced the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline. Recent news from April 2026 highlighted that brelovitug met its primary endpoint in the Phase 2b portion of the AZURE-1 study for chronic hepatitis delta virus, indicating pipeline momentum. The company reported strong commercial growth in 2025, with net product sales exceeding guidance, and anticipates global net product sales between $630 million and $650 million for 2026.